Screener
USANA Health Sciences USNA Rise — Cost of Sales
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by USANA Health Sciences in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: USANA Health Sciences’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:35 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000896264-26-000034
| Line item | Core Nutritional | Hiya | Rise | Total |
|---|---|---|---|---|
| Net sales (1) | $204,399 | $32,150 | $13,669 | $250,218 |
| Less: | ||||
| Cost of sales | 36,749 | 9,983 | 12,704 | 59,436 |
| Brand Partner incentives | 88,654 | — | — | 88,654 |
| Selling, general and administrative (2) | 60,747 | 24,771 | 2,736 | 88,254 |
| Segment earnings (loss) from operations | $18,249 | $(2,604) | $(1,771) | $13,874 |
| Reconciliation of segment earnings from operations | ||||
| Interest income | 437 |
Item 1. FINANCIAL STATEMENTS
FAQ
- What is USANA Health Sciences's rise — cost of sales?
- USANA Health Sciences (USNA) reported rise — cost of sales of $12.7M in Q1 2026.
- What does rise — cost of sales mean?
- Reflects the direct costs associated with the production, manufacturing, and procurement of goods sold within the Rise segment. Monitoring this metric helps assess the direct profitability and production efficiency of this specific product line.
Ask your AI about USANA Health Sciences's rise — cost of sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude